FAM
PRQR icon

Flaharty Asset Management’s ProQR Therapeutics PRQR Stock Holding History

Flaharty Asset Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,000
Closed -$2.66K – 392
2025
Q1 		$2.66K Buy
+2,000
New +$4.26K ﹤0.01% 426
2024
Q4 		– Sell
-2,000
Closed -$3.64K – 345
2024
Q3 		$3.64K Buy
+2,000
New +$3.75K ﹤0.01% 389
2023
Q4 		– Sell
-2,000
Closed -$2.6K – 360
2023
Q3 		$2.6K Buy
+2,000
New +$3.15K ﹤0.01% 417

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Flaharty Asset Management's PRQR Position: Q2 2025 in Review

Flaharty Asset Management sold out of ProQR Therapeutics (PRQR) in Q2 2025, closing a stake of 2,000 shares — an estimated $2.66K sold.

Flaharty Asset Management first reported a position in PRQR in Q3 2023 and held it in 3 quarters. The position peaked at $3.64K in Q3 2024. 62 funds tracked by Wall St. Rank hold PRQR as of Q2 2025.

  • Flaharty Asset Management reported no remaining ProQR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Flaharty Asset Management sold 2,000 ProQR Therapeutics shares in Q2 2025, an estimated $2.66K.
  • Flaharty Asset Management first reported a position in ProQR Therapeutics in Q3 2023 and held it in 3 quarters.
  • Flaharty Asset Management's ProQR Therapeutics position peaked at $3.64K in Q3 2024.
  • 62 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2025.

Based on Flaharty Asset Management's 13F filing for Q2 2025, filed 8 Aug 2025.